# Kyto Technology and Life Science Inc

> Kyto Technology and Life Science Inc is a VC fund backing Health Care. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Los Altos Hills, United States
- Total investments: 10
- Last investment: Oct 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kyto-technology-and-life-science-inc/about/
- Website: https://kytotech.com/

Kyto Technology and Life Science Inc is a VC fund in Los Altos Hills focused on Health Care and Medical. KYTO’s strategy is to develop a specialized vehicle for early stage technology and life science companies.

## Contacts

5 contacts available for Kyto Technology and Life Science Inc. Shizune tracks 2 team members at Kyto Technology and Life Science Inc. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kyto-technology-and-life-science-inc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.4M–$6.3M |
| Series A | $6M–$15M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 40% |
| Medical | 3 | 30% |
| Biotechnology | 3 | 30% |
| Medical Device | 3 | 30% |
| Health Diagnostics | 3 | 30% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 50% |
| Series A | 2 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 60% |
| Canada | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Ricci | Director, Portfolio Management | 0 | https://shizune.co/investors/profile/john-ricci-2 |
| Thomas L. Vogelsong | Angel Investor, Life Science Advisor, and Directo | 0 | https://shizune.co/investors/profile/thomas-l-vogelsong |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $14.6M | Series A | Oct 10, 2023 |  |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $15M | Series A | Oct 10, 2023 |  |
| Avisi Technologies | Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $6.3M | Seed | Oct 01, 2023 |  |
| Spintly | Spintly is a wireless cloud-based access control platform which enables users to access doors using their smartphones and eliminates more than 95% of access control cabling in buildings. Current Access control systems need extensive wiring and are bulky, occupying a ton of space in server rooms. Current access and identity management systems arenot smartphone friendly and getting data to the cloud from such systems is not trivial. Spintly cloud based smart access control system uses a wireless BLE-mesh network of access control readers to eliminate the back-end access control wiring in a building and empowers users by letting them use their smartphone as an access control device. Spintly access control system is connected to the cloud 24x7 through a wireless gateway and allows real-time monitoring of access data. Spintly offers access management solutions to Enterprises, Co-working spaces, Co-living spaces, Hospitality clients and residential communities. | $1.4M | Seed | Nov 10, 2022 |  |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $15M | Series A | Mar 03, 2022 |  |
| Rhaeos | Rhaeos, the world's first wearable shunt monitor, aims to improve the quality care for patients with hydrocephalus through a novel, thermal biosensor. Developed within Northwestern University with collaboration between Dr. John Rogers, McCormick School of Engineering, Feinberg School of Medicine and Kellogg School of Management, Rhaeosrepresents a unique multidisciplinary translational effort for an important clinical need. | $2.2M | Seed | Dec 24, 2021 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $2.5M | Seed | Nov 15, 2021 |  |
| Single Pass | Single Pass is a developer of a disposable bipolar electrocautery device that can cauterize deep tissue through a guide needle. |  | Seed | Jul 09, 2021 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $2.5M | Seed | Jun 28, 2021 |  |
| Astrocyte Pharmaceuticals | Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M | Series A | May 03, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [Boutique Venture Partners](https://shizune.co/investors/profile/boutique-venture-partners) — VC Fund, 3 deals together
- [Graphene Ventures](https://shizune.co/investors/profile/graphene-ventures) — VC Fund, 3 deals together
- [Cur8 Capital](https://shizune.co/investors/profile/ifg-vc) — VC Fund, 3 deals together
- [Leva Capital](https://shizune.co/investors/profile/leva-capital) — VC Fund, 3 deals together
- [Sidecar Angels](https://shizune.co/investors/profile/sidecar-angels) — VC Fund, 3 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in Canada](https://shizune.co/investors/medical-device-vc-funds-canada)

## FAQ

### What does Kyto Technology and Life Science Inc invest in?

Kyto Technology and Life Science Inc invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Kyto Technology and Life Science Inc's check size?

Kyto Technology and Life Science Inc typically joins rounds of $1.4M–$6.3M at Seed and $6M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kyto Technology and Life Science Inc participates in.

### How do I contact Kyto Technology and Life Science Inc?

Public channels for Kyto Technology and Life Science Inc include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kyto Technology and Life Science Inc?

The team at Kyto Technology and Life Science Inc includes John Ricci (Director, Portfolio Management) and Thomas L. Vogelsong (Angel Investor, Life Science Advisor, and Directo). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co